Skip to main content
Triangle logo TriangleCheck this trial

Olaparib + Estradiol (PHOEBE)

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

  • RegistryNCT05900895
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAdvanced ER-Positive HER2-Negative Breast Cancer
  • SponsorMary D Chamberlin
How PHOEBE works1 min

The drug

What is being tested.

Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.

17b-estradiol will be taken orally three times per day.

Patients with endocrine-resistant ER+/HER2- breast cancer are eligible. Patients will be treated with the combination of 17b-estradiol and olaparib for 2 cycles, and then treated with single-agent 17b-estradiol until disease progression. Clinical benefit, progression-free survival, objective response, tumor metabolic response, and toxicity will be determined.

The study

How the trial runs.

Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Post-menopausal women with ER+/HER2- breast cancer.
  • Metastatic or locoregional recurrence not amenable to treatment with curative intent.
  • Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.

Not sure whether you would qualify?

Would this trial apply to me?

7-day free trial, then $9 a month. Cancel anytime.

More in BreastBrowse Breast →

HR+/HER2- Breast Cancer Brain MetastasesNCT04923542

Radiosurgery + Abemaciclib

SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

H. Lee Moffitt Cancer Center and Research InstituteOpen the brief

Mesothelin-Expressing TumorsNCT06623396Papers

M28z1XXPD1DNR CAR

Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Memorial Sloan Kettering Cancer CenterOpen the brief

Triple Negative Breast CancerNCT05504707Papers

HER2 - primed Dendritic cells

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

H. Lee Moffitt Cancer Center and Research InstituteOpen the brief

Triple-Negative Breast CancerNCT06324240

Personalized TMV Tumor Vaccine

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Emory UniversityOpen the brief